NCT00400764View on ClinicalTrials.gov

A Study of Dulanermin in Combination With Rituximab in Subjects With Follicular and Other Low Grade, CD20+, Non-Hodgkin's Lymphomas

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

May 31, 2010

Conditions
Non-Hodgkin's Lymphoma
Interventions
DRUG

Dulanermin

Dulanermin was administered by intravenous (IV) infusion over 1 hour on days 1-5 of each 21-day cycle.

DRUG

Rituximab

Rituximab was administered by intravenous (IV) infusion at 375 mg/m\^2 weekly for up to eight doses.

Sponsors

Lead Sponsor

Genentech, Inc.

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

Genentech, Inc.

INDUSTRY